300% rise in net profit in Q3; Analysts see exciting times ahead for this mid-cap firm

This is despite a 140% jump in the pharmaceutical firm’s stock prices over the past year

Related Keywords

India , ,Dalal Street ,Indian Pharmaceutical Market ,Diazepam Gel ,Medical Representative ,Active Pharmaceutical Ingredient ,Axis Securities ,Lupin ,Lupin Shares ,Lupin Share Price ,Lupin Q3 Results ,Upin Q3 Net Profit ,Midcap Stock ,